{"id":56179,"date":"2023-04-25T12:04:23","date_gmt":"2023-04-25T10:04:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/"},"modified":"2023-04-25T12:04:23","modified_gmt":"2023-04-25T10:04:23","slug":"caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/","title":{"rendered":"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring<\/i><\/p>\n<p>BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211;CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today announced that it will showcase the latest developments across its AlloSeq\u00ae* portfolio<sup> <\/sup>during the 36<sup>th<\/sup> European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/4\/CareDx_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/21\/CareDx_Logo.jpg\"><\/a><\/p>\n<p>\n\u201cWe look forward to participating in this meeting and presenting our latest innovations for the European transplant community with our AlloSeq* portfolio of lab products for research and clinical use pre- and post-transplantation,\u201d said Reg Seeto, CEO and President of CareDx. \u201cWe are committed to advancing the field of immunogenetics and histocompatibility and take great pride in supporting this important event as a platinum sponsor.\u201d<\/p>\n<p>\nCareDx will be on hand to display its leadership in serving European laboratories, researchers, and clinicians with its best-in-class product portfolio of next-generation sequencing (NGS) based AlloSeq* products, which enables best-in-class care both pre- and post-transplantation.<\/p>\n<p>\nFor pre-transplant, CareDx offers AlloSeq Tx* HLA typing solutions. For post-transplant, CareDx offers AlloSeq HCT* chimerism testing<sup> <\/sup>and AlloSeq cfDNA* for labs to assess transplanted stem cells and organ health, respectively. CareDx also provides pre-transplant HLA typing and post-transplant surveillance testing for customers through its service lab in Stockholm, Sweden, for clinical research.<\/p>\n<p>\nCareDx will sponsor a symposium \u201cBreaking New Ground: Innovative Pre- and Post-Transplant Solutions to Improve Allograft Outcomes\u201d on Thursday, April 27. The event will be moderated by Curtis Lind, CareDx Vice President and Head of R&amp;D products. Panelists and topics include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Monica Irina Dutescu M,D., Ph.D.<\/b><b>,<\/b><b> <\/b>National HLA Laboratory, National Institute of Blood Transfusion Prof. Dr. C.T. NICOLAU Bucharest, Romania: <i>High Resolution HLA Typing with AlloSeq Tx \u2013 the Experience of National HLA Laboratory, Bucharest.<\/i><\/li>\n<li>\n<b>Miguel Alcoceba Ph.D.<\/b><b>,<\/b> Department of Haematology, University Hospital of Salamanca (HUS-IBSAL) Salamanca, Spain: <i>Comparison of Next-Generation Sequencing and Short-Tandem Repeats to Monitor Chimerism Analysis.<\/i><\/li>\n<li>\n<b>Olivier Aubert M.D., Ph.D.<\/b><b>,<\/b> Necker-Enfants Malades Hospital &#8211; Paris Transplant Group, Paris, France: <i>dd-cfDNA in Allograft Rejection and Risk Assessment.<\/i><\/li>\n<\/ul>\n<p>\n\u201cI look forward to participating in the CareDx sponsored symposium and showing how its innovative HLA typing solutions represent a strong, efficient, and user-friendly technique for pre-transplant testing, that provides reliable, accurate results. I will also demonstrate how the use of its hybrid capture method can also provide the best coverage, high level of transplant matching and low rates of ambiguity in one product,\u201d said Monica Irina Dutescu, M.D., Ph.D., National Institute of Blood Transfusion, Bucharest.<\/p>\n<p>\nThe following nine AlloSeq* oral presentations and posters will be presented at the meeting.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>Title<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>First Author<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Poster<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>Featuring AlloSeq Tx17 and Hybrid Capture<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nThe expanded role of microRNAs in controlling the HLA class I phenotype: Relationship between the 3\u2019 UTR and post-transcriptional Gene Regulation<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nPanagiotis Mallis<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nOral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nDetection of HLA-A and HLA-J haplotype diversity from next-generation sequencing data in commercially available samples.<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nJessica Edwards<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nP100<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nIdentification of the novel HLA-DPB1*02:01:68 allele in a Greek individual<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nDiamanto Kouniaki<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nP127<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nIdentification of the novel HLA-A*01:426 allele in a Greek individual<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nDiamanto Kouniaki<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nP129<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nIdentification of the novel HLA-A*02:09:01:04 allele in a Greek individual<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nDiamanto Kouniaki<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nP130<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl bwvertalignm\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>Featuring AlloSeq HCT<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nEvaluation of the Magelia for automated purification of CareDx AlloSeq HCT kit libraries in the context of post-hematopoietic stem cells transplantation chimerism assessment<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nCoralie Frassati<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nP124<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl bwvertalignm\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n<b>Featuring AlloSeq cfDNA Assay and Software<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nClinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nPascal Pedini<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nOral<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nDonor specific HLA-DPw antibodies in a highly sensitized kidney transplant recipient \u2013 a case report<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nDolores Hrusovar<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nP74<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nResults of the 6 Months Post-Transplant Surveillance in patients transplanted with preformed donor-specific anti-HLA antibodies (DSA) by Adding Donor-Derived Cell-Free DNA Testing<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwvertalignm bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nMar\u00eda Lasa-L\u00e1zaro<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nP121<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n*AlloSeq Tx, AlloSeq HCT and AlloSeq cfDNA<b> <\/b>are available as CE\/IVD in the EU and in the U.K., and Research Use Only for the rest of the world. AlloSeq Service is available as Research Use Only. Research Use Only products are not to be used for diagnostic procedures. AlloSeq cfDNA is only available outside of the United States. For local regulatory status, please contact CareDx.<\/p>\n<p>\n<b>About CareDx \u2013 The Transplant Company<\/b><\/p>\n<p>\nCareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.caredx.com%2F&amp;esheet=53387069&amp;newsitemid=20230425005495&amp;lan=en-US&amp;anchor=CareDx.com&amp;index=1&amp;md5=726fe8d16572fe56f752fa125ebd231a\" rel=\"nofollow noopener\" shape=\"rect\">CareDx.com<\/a>.<\/p>\n<p>\n<b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx\u2019s AlloSeq* portfolio of lab products,<sup> <\/sup>as well as CareDx\u2019s leading participation at the 36th European Immunogenetics and Histocompatibility Conference (the \u201cParticipation\u201d). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its AlloSeq* portfolio or Participation; general economic and market factors; and other risks discussed in CareDx\u2019s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023 and other reports that CareDx has filed with the SEC. Any of these may cause CareDx\u2019s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx\u2019s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>CareDx, Inc.<\/b><br \/>Media Relations<br \/>\n<br \/>Anna Czene<br \/>\n<br \/>818-731-2203<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;l&#x74;&#x6f;&#58;ac&#x7a;&#x65;&#110;e&#x40;&#x63;&#97;&#114;e&#x64;&#x78;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;&#x63;&#x7a;&#x65;&#x6e;&#x65;&#x40;&#x63;&#x61;&#x72;&#x65;&#x64;&#x78;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p>\nInvestor Relations<br \/>\n<br \/>Greg Chodaczek<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:I&#110;&#118;&#101;&#115;&#116;&#111;&#114;&#64;&#99;&#97;&#x72;&#x65;&#x64;&#x78;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x49;&#x6e;&#118;&#101;s&#x74;&#x6f;&#x72;&#64;ca&#x72;&#x65;&#100;&#120;&#46;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211;CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today announced that it will showcase the &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56179","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211;CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today announced that it will showcase the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T10:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/21\/CareDx_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference\",\"datePublished\":\"2023-04-25T10:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/\"},\"wordCount\":1010,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005495\\\/en\\\/1498832\\\/21\\\/CareDx_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/\",\"name\":\"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005495\\\/en\\\/1498832\\\/21\\\/CareDx_Logo.jpg\",\"datePublished\":\"2023-04-25T10:04:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005495\\\/en\\\/1498832\\\/21\\\/CareDx_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005495\\\/en\\\/1498832\\\/21\\\/CareDx_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/","og_locale":"en_US","og_type":"article","og_title":"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference - Pharma Trend","og_description":"Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211;CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers \u2013 today announced that it will showcase the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-25T10:04:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/21\/CareDx_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference","datePublished":"2023-04-25T10:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/"},"wordCount":1010,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/21\/CareDx_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/","url":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/","name":"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/21\/CareDx_Logo.jpg","datePublished":"2023-04-25T10:04:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/21\/CareDx_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230425005495\/en\/1498832\/21\/CareDx_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/caredx-showcases-latest-advances-across-alloseq-lab-products-portfolio-at-the-36th-european-immunogenetics-and-histocompatibility-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56179"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56179\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}